Hi everyone, Sean here from Courage Against Cancer. I’m beyond proud to share an incredible milestone — our foundation has just submitted and anticipate signing its first Sponsored Research Agreement with MD Anderson Cancer Center soon!
This marks the official launch of a preclinical study on ivermectin and mebendazole in ovarian cancer, the beginning of our mission to bring forward the first non-chemo, non-radiation-based therapy for FDA review.
In this video, I’ll explain what this collaboration means for patients, researchers, and the future of integrative oncology — and how your support makes all of this possible.
2 replies on “Coco’s Big News: Courage Against Cancer Joins Forces with MD Anderson!”
[…] to its coverage of new cancer treatment approaches and emerging breakthroughs — and to its active preclinical research support through partnerships with institutions like MD Anderson — is the same rigor that must be brought to content system design. Education at scale requires […]
[…] contribution, large or small, directly supports our ongoing preclinical study on ovarian cancer, educational outreach, and future clinical trial development.✨ Join us in transforming courage […]